Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last kr336.50 DKK
Change Today +3.00 / 0.90%
Volume 168.5K
BAVA On Other Exchanges
Symbol
Exchange
Copenhagen
OTC US
OTC US
Frankfurt
As of 11:04 AM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

bavarian nordic a/s (BAVA) Snapshot

Open
kr335.50
Previous Close
kr333.50
Day High
kr339.50
Day Low
kr333.00
52 Week High
04/10/15 - kr393.00
52 Week Low
09/2/14 - kr106.50
Market Cap
9.4B
Average Volume 10 Days
189.5K
EPS TTM
kr2.52
Shares Outstanding
27.8M
EX-Date
--
P/E TM
133.8x
Dividend
--
Dividend Yield
--
Current Stock Chart for BAVARIAN NORDIC A/S (BAVA)

Related News

No related news articles were found.

bavarian nordic a/s (BAVA) Related Businessweek News

No Related Businessweek News Found

bavarian nordic a/s (BAVA) Details

Bavarian Nordic A/S, a biotechnology company, researches, develops, and manufactures novel cancer immunotherapies and vaccines for infectious diseases. The company markets IMVANEX, a non-replicating smallpox vaccine in Europe, as well as markets under the IMVAMUNE name in Canada. It is developing PROSTVAC, a targeted immunotherapy candidate for the treatment of metastatic castration-resistant prostate cancer, which is in Phase III clinical trials in collaboration with the National Cancer Institute; and CV-301, an active cancer immunotherapy product candidate, which is in Phase II clinical trials to treat colon, breast, and other cancers. The company is also involved in the development of IMVAMUNE, a non-replicating vaccine for the treatment of smallpox that is in Phase III clinical trials in the United States; and IMVAMUNE freeze-dried to treat smallpox in the liquid frozen form, which is in Phase II clinical trials. In addition, it is developing various products to treat infectious diseases that are in preclinical stage, including MVA-BN Anthrax for the treatment of anthrax in humans and animals; MVA-BN Filo vaccine for ebola and marburg; MVA-BN vaccine for selected biological threats, such as foot-and-mouth disease virus and burkholderia; and MVA-BN respiratory syncytial virus vaccine. Further, the company is involved in the development of MVA-BN Brachyury, a novel, active immunotherapy designed to induce a robust T cell immune response against Brachyury, which is in Phase I trial. Bavarian Nordic A/S was founded in 1994 and is headquartered in Kvistgaard, Denmark.

421 Employees
Last Reported Date: 05/5/15
Founded in 1994

bavarian nordic a/s (BAVA) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

bavarian nordic a/s (BAVA) Key Developments

Bavarian Nordic A/S Announces Results from Phase I Ebola Virus Disease Study

Bavarian Nordic A/S announced preliminary results from a Phase I first-in-human study with the Ebola prime-boost vaccine regimen, which includes Bavarian's MVA-BN Filo vaccine and the AdVac vaccine from the Janssen Pharmaceutical Companies of Johnson & Johnson. In the study, conducted by the Oxford Vaccines Group, 72 healthy volunteers were randomized into four groups receiving the vaccine regimen or placebo. A priming dose of either Ad26.ZEBOV or MVA-BN Filo was administered at day 1 and booster doses of the other vaccine were administered after 28 or 56 days. An open label arm with 15 healthy volunteers is also investigating a shorter prime-boost interval of 14 days for Ad26.ZEBOV prime and MVA-BN Filo boost. Preliminary data from this ongoing study shows that the prime-boost vaccine regimen was immunogenic, regardless of the order of vaccine administration, and that both vaccines only provoked temporary reactions normally expected from vaccination. Immune responses post boost appeared to be well balanced with the induction of humoral and cellular immune response components, the latter being comprised of highly polyfunctional CD8+ and CD4+ T cell responses. These results confirm the preclinical results previously reported and warrant further investigation of the vaccine regimen in Phase II studies and efficacy trials.

Bavarian Nordic A/S Announces Earnings Results for the First Quarter Ended March 31, 2015; Provides Earnings Guidance for the Year 2015

Bavarian Nordic A/S announced earnings results for the first quarter ended March 31, 2015. For the quarter, the company has reported that net profit for the first quarter ended March 31, 2015 was DKK 45.4 million, or DKK 1.6 per basic share, compared to DKK 1.2 million, or DKK 0 per basic share, for the same quarter ended March 31, 2014. Revenue for the first quarter ended March 31, 2015 was DKK 234.8 million, compared to DKK 285.9 million for the same quarter ended March 31, 2014. Loss before interest and taxes for the first quarter ended March 31, 2015 was DKK 40.2 million, compared to an income before interest and taxes of DKK 3.4 million for the same quarter ended March 31, 2014. For the year 2015, the company expects revenue to be DKK 1.0 billion.

Bavarian Nordic A/S Announces Positive Results from Two Pivotal Clinical Studies of IMVAMUNE Smallpox Vaccine

Bavarian Nordic A/S announced results from the first of two pivotal Phase 3 studies of the liquid-frozen formulation of IMVAMUNE® supporting a Biologics License Application for U.S. approval of the vaccine. In addition, the Company announced results from a pivotal Phase 2 study of freeze-dried IMVAMUNE smallpox vaccine supporting the clinical requirements for an Emergency Use Authorization, which would allow for stockpiling of this next-generation of the vaccine. The Phase 3 was designed as a randomized, double-blind, placebo-controlled study in 4,000 vaccinia-naïve subjects. Three thousand (3,000) subjects were vaccinated with three different manufacturing lots of the liquid-frozen IMVAMUNE formulation (1,000 subjects per lot) and compared to 1,000 subjects that received placebo. The three lots of IMVAMUNE induced equivalent antibody responses, meeting the primary endpoint of the study, while the favorable safety profile of IMVAMUNE was confirmed in this clinical study performed to date. Despite close cardiac monitoring of all subjects, no serious adverse reactions were reported among the 3,000 subjects vaccinated with IMVAMUNE, confirming the results of a smaller Phase 2 placebo controlled study that was recently publishedi and clearly differentiates the safety profile of IMVAMUNE when compared to traditional smallpox vaccines (e.g. ACAM2000® approved in the U.S.) that have recorded high rates of cardiac complications in healthy vaccinees (5.73 events per thousand immunizationsii). The Phase 2 study compared the safety and immunogenicity of a freeze-dried and a liquid-frozen formulation of IMVAMUNE and enrolled 650 vaccinia-naïve healthy subjects who were randomized to receive either formulation of IMVAMUNE. The freeze-dried vaccine induced an equivalent antibody response as the liquid-frozen version, meeting the primary endpoint of the study. Also both formulations recorded a similar safety profile, confirming that the clinical data generated cumulatively in more than 7,600 vaccinated subjects is relevant for both formulations of IMVAMUNE. The results provide the final clinical data required to support stockpiling of the freeze-dried version of IMVAMUNE in the U.S. Strategic National Stockpile. Supported by a contract option of USD 22 million exercised by the Biomedical Advanced Research and Development Authority (BARDA) in 2014, Bavarian Nordic is currently working to transfer the freeze-drying process to a new manufacturing line with a larger commercial capacity. These manufacturing activities remain on-track to be finalized this year, which is the final step towards meeting the regulatory requirements to stockpile the freeze-dried version of IMVAMUNE.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BAVA:DC kr336.50 DKK +3.00

BAVA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bioporto A/S kr2.90 DKK -0.02
Chimerix Inc $41.85 USD +0.24
Emergent Biosolutions Inc $31.86 USD +0.11
GeoVax Labs Inc $0.18 USD +0.015
Valneva SE €4.08 EUR -0.08
View Industry Companies
 

Industry Analysis

BAVA

Industry Average

Valuation BAVA Industry Range
Price/Earnings 100.0x
Price/Sales 8.2x
Price/Book 7.5x
Price/Cash Flow 136.9x
TEV/Sales 6.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BAVARIAN NORDIC A/S, please visit www.bavarian-nordic.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.